Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib Long-Term Extension in Crohn's Disease
NCT02914600Phase 3Terminated
- Sponsor
- Galapagos NV
- Start
- Mar 2017
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 40
01
Overview
Phase 3, double-blind trial of filgotinib in Crohn's disease (3 arms), sponsored by Galapagos NV. Primary endpoint: Treatment Emergent Adverse Events at Week 312. Started Mar 2017; status: terminated.
02
Drugs
filgotinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02914600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914600.